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Abstract
Monitoring HIV subtype distribution is important for understanding transmission dynamics. Subtype B has
historically been dominant in Australia, but in recent years new clades have appeared. Since 2000, clade data
have been collected as part of HIV surveillance in South Australia. The aim of this study was to evaluate the
prevalence of and risk factors for HIV-1 non-B subtypes. The study population was composed of newly diag-
nosed, genotyped HIV subjects in South Australia between 2000 and 2010. We analyzed time trends and subtype
patterns in this cohort; notification data were aggregated into three time periods (2000–2003, 2004–2006, and
2007–2010). Main outcome measures were number of new non-B infections by year, exposure route, and other
demographic characteristics. There were 513 new HIV diagnoses; 425 had information on subtype. The majority
(262/425) were in men who have sex with men (MSM), predominantly subtype B and acquired in Australia.
Infections acquired in Australia decreased from 77% (2000–2003) to 64% (2007–2010) ( p = 0.007) and corre-
spondingly the proportion of subtype B declined from 85% to 68% ( p = 0.002). Non-B infections were pre-
dominantly (83%) heterosexual contacts, mostly acquired overseas (74%). The majority (68%) of non-B patients
were born outside of Australia. There was a nonsignificant increase from 1.6% to 4.2% in the proportion of
locally transmitted non-B cases (p = 0.3). Three non-B subtypes and two circulating recombinant forms (CRFs)
were identified: CRF_AE (n = 41), C (n= 36), CRF_AG (n = 13), A (n= 9), and D (n= 2). There has been a sub-
stantial increase over the past decade in diagnosed non-B infections, primarily through cases acquired overseas.
Introduction
HIV-1 is divided into distinct lineages, Major (M),Outlier (O), New (N), and P, most likely reflecting four
separate introductions of simian immunodeficiency viruses
into humans.1–3 Analysis of nucleotide sequence variations of
the reverse transcriptase and protease regions of the HIV pol
gene is routinely conducted to determine resistance to anti-
retroviral drugs. Thus this region can be also exploited to
define HIV into subtypes, and track HIV evolution and di-
versity.4 Over 99% of the HIV pandemic is attributable to the
M lineage4 and there are at least nine phylogenetically distinct
subtypes: A–D, F–H, J, and K.5,6 Viruses of different subtypes
can also recombine and create hybrid or circulating recom-
binant forms (CRFs) of which there are currently 52.4,7
Historically, HIV subtypes and CRFs have been broadly
linked with geographic location and risk group.8 However,
subtype distribution of the global HIV pandemic has diver-
sified extensively through mutation and recombination,
partly driven by a combination of population mobility, sexual
mixing, and the impact of antiretroviral therapies.3,9 Subtype
and CRF differences have been linked to disease progression,
transmission route, pathogenicity, transmissibility, accuracy
of current diagnostic assays, response to therapy, and devel-
opment of drug resistance mutations.3,5,10,11 Other factors can
also influence these characteristics, which makes it difficult to
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establish the independent effects of subtype, but this vari-
ability potentially has major clinical and epidemiological
significance.3,12
Surveillance systems have been in place since the beginning
of the global pandemic, and in recent years have incorporated
molecular epidemiology as a tool both for surveillance of
HIV-1 genetic diversity and to monitor transmission and
geographic pathways of genetic variants.3,13–15 For example,
recent mapping of HIV strains in Asia revealed a large genetic
diversity, including two new CRFs and transmission of new
recombinant HIV-1 subtypes.14,16
Historically, subtype B has predominated in Western
countries5,6 where transmission is primarily through male-to-
male sex.6,8,17 However, subtype B accounts for only 11% of
global HIV infections,9 and the prevalence of non-B infections
in Western countries is increasing. Recent studies in France
have found non-B prevalence rates of 42–48% in newly di-
agnosedHIV infections.18 In Italy, non-B prevalence rates rose
from 25% in 2000 to over 60% in 2008, with African ethnicity
and heterosexual acquisition as independent predictors.6 In a
Washington cohort the non-B prevalence rate was 13%,13 and
in one broad population-based study in the United States a
national non-B prevalence rate of 5.1% was reported in newly
diagnosed infections.19 In a very recently published Austra-
lian study, Chibo and Birch (2012) found a non-B prevalence
rate of 22% in a Victorian cohort.20
Parallel to this genetic diversity, there are increasing data
on subtype-specific differences, related to genotyping, trans-
mission efficiency, disease progression, vaccine development,
and drug therapy.12,21 Though subtype B has always ac-
counted for a relatively small percentage of the total pan-
demic, it has historically been the predominant global
reference clade for assay development, drug resistance test-
ing, and antiretroviral susceptibility.1,5,13
In 2000, South Australia became the first state to integrate
drug resistance testing as part of the routine HIV reporting
and surveillance system. The resulting data provide the first
analysis of Australian trends and molecular epidemiology of
HIV subtype distribution over the past decade. We report a
pattern of increasing non-B subtypes in South Australia,
though subtype B still characterizes the predominant HIV
infection in this cohort.
Materials and Methods
Surveillance system for HIV in South Australia
AIDS and HIV notification was commenced in South
Australia in 1985 and 1991, respectively. For each new person
diagnosed, a standardized form is completed, which includes
demographic, epidemiological, and clinical information.
Where possible, an in-depth interview is also conducted.
In 2000, South Australia became the first jurisdiction to
conduct routine genotypic and drug resistance testing as part
of an enhanced surveillance system. This genotype informa-
tion is housed on a separate database, but is linked to the
notification system via patient number. The South Australian
Health Department is the custodian of both databases. For the
current study, the two databases were merged to create a
combined dataset. Patient identifiers such as name and ad-
dress were removed, and limited demographic, epidemio-
logical, and clinical data were retained, including gender, age,
reported continent of birth, reported exposure route, and re-
ported location of infection acquired (overseas/Australia).
This studywas approved by both the SouthAustralian Health
and Flinders University Research Ethics Committees.
Study population and design
Five hundred and thirteen people newly diagnosed with
HIV between 2000 and 2010 were identified from the South
Australian HIV notification database, and 425 were retro-
spectively selected from this dataset according to the follow-
ing inclusion criteria: no previously documented positive
diagnosis and a plasma-derived RNA pol sequence available
for genotyping, takenwithin 12 months of diagnosis. For each
patient, notification data, including location where the infec-
tion was acquired, were collected through a standardized
form and interview at the time of diagnosis, as part of the
routine notification protocol.
HIV-1 genotyping
Blood was collected for routine drug resistance testing,
viral load, and CD4 + cell count. Due to the number of routine
samples, patient plasma was stored at - 20C until genotyp-
ing. Past experience has demonstrated negligible degradation
of virus nucleic acid. Viral RNA was extracted and a 1098
nucleotide fragment of the pol gene that encompasses the
protease and reverse transcriptase genes was sequenced in
both directions, using RT-PCR and dye terminator sequencing
with standard commercial reagents. Sequences were assem-
bled and proofread to obtain a contiguous sequence using
Kodon 2.4 (Applied Maths, Sint-Martens-Latem, Belgium).
The entire sequence was submitted to the Stanford HIV Drug
Resistance Database for the determination of virus subtype
and for drug resistance interpretation. Although phylogenetic
and subtype analysis was carried out on the entire 1098 nu-
cleotide fragment of the pol gene, only the protease regionwas
used in subsequent epidemiological analyses for simplicity.
Statistical methods
HIV genetic and notification datawere linked and analyzed
using subtype as the dependent variable, and year, country of
origin, where infection was acquired, reported risk exposure,
and age as explanatory variables. Notification data were ag-
gregated into three time periods (2000–2003, 2004–2006, and
2007–2010) of relatively equal numbers and with significant
power to conduct statistical tests. Categorical variables were
analyzed using chi square tests-for-trend and Fishers exact
test to identify subtype-specific characteristics. Multivariate
analysis was performed using logistic regression. Variables
used are described in Table 1. Significance levels were set at
p £ 0.05. All data were analyzed using the software package
Stata 10.1 (StataCorp LP, College Station, TX).
Results
South Australian HIV population; genotype
There were 513 reported diagnoses between 2000 and 2010,
and 425 (83%) had genotypes determined. The annual num-
ber of diagnoses has remained relatively stable over the past
11 years (mean= 47/year). Demographic and other charac-
teristics of those for whom genotypes were obtained (n = 425)
were very similar to those for the total diagnosed population
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(n= 513, Table 1). There were 101 cases (24%) of HIV non-B
subtypes among these genotyped specimens (Fig. 1). Themost
common non-B infection was CRF_AE (41) followed by sub-
type C (36), CRF_AG (13), subtype A (9), and subtype D (2).
Though new diagnoses in South Australia have remained
stable over time, there has been a significant change in sub-
type distribution within newly diagnosed individuals. The
proportion of non-B infections increased from 15% (2000–
2003) to 21% (2004–2006) to 32% (2007–2010) ( p= 0.002). In
2010, the proportion of non-B infections was 47% (Fig. 2).
Location infection acquired
As well as an increase in non-B subtypes over time, there
was a significant increase in the proportion of infections ac-
quired overseas from 23% (2000–2003) to 37% (2007–2010)
( p = 0.006). When analyzed by subtype, 85% of the 101 non-B
infections were reported to be acquired overseas and were
composed of 95% (34/36) of the total subtype C infections,
81% (36/41) of the CRF_AEs, 77% (10/13) of the CRF_AGs,
89% (8/9) of the As, and 50% of the (1/2) Ds.
In contrast to non-B infections, only 10% of the 324 B in-
fections were acquired overseas ( p < 0.0001).
Among the 72% of cases (305/425) determined to have
been acquired within Australia, 95% were clade B (Table 1).
However, new local non-B diagnoses have increased from
two cases in the first time period to six in the second and seven
in the third (Fig. 2). Of these 15 local transmissions, nine were
female and six reported being born in Australia. Of the six
males who acquired HIV locally, four reported being born in
Australia.
Reported risk exposure, gender, and age at diagnosis
The majority of genotyped subjects were men who have
sex with men (MSM) (62%), although the proportion has
dropped from 72% (2000–2003) to 61% (2004–2006) and 55%
in the most recent time period (2007–2010). Correspondingly,
the proportion of reported heterosexually acquired HIV
increased from 27% (2000–2003) to 35% (2004–2006) and 40%
(2007–2010).
Of the 262 genotyped MSM infections, nearly all (97%)
were subtype B, and 90% were acquired in Australia. The
remaining 10% acquired overseas were nearly all subtype B,
but three had CRF_AE. Of the 146 genotyped heterosexual
infections, 43% were subtype B (Table 1) and 43% (63/146)
were acquired in Australia. The remaining 57% acquired
overseas were nearly all (89%) non-B (36% C, 35% CRF_AE,
18%A/D/CRF_AG). The proportion of female infections was
significantly higher in the non-B cohort (36% or 36/101)
compared to the B cohort (6% or 18/324) ( p< 0.0001).
Approximately one-tenth of genotyped patients (45/425)
were under the age of 25 years when diagnosed (32 males and
13 females). The observed frequency of non-B infections in the
Table 1. Characteristics of Newly Diagnosed
HIV-Infected Patients in South Australia 2000–2010
All reported
diagnoses
Genotype
obtained
Number
(%) B
Characteristics (n = 513) (n = 425) (n = 324)
Gender
Male 437 (85) 371 (87) 306 (83)
Female 76 (15) 54 (13) 18 (33)
Age at HIV diagnosis (years)
< 25 54 (11) 45 (11) 27 (60)
25 + 458 (89) 380 (89) 297 (78)
Unknowna 1 (0.1)
Region of birth
Australia/Oceania 277 (54) 240 (57) 211(88)
Africa 53 (10) 43 (10) 3 (7)
Asia 38 (7) 24 (6) 8 (33)
America 8 (2) 7 (2) 6 (86)
Europe 39 (8) 26 (6) 21 (81)
Not reporteda 98 (19) 85 (20) 75 (88)
Risk exposure
Heterosexual 180 (35) 146 (34) 62 (43)
MSM 314 (61) 262 (62) 255 (97)
Other 16 (3) 3 (1) 4 (100)
Unknowna 3 (1) 14 (3) 3 (23)
Location HIV acquired
Australia 344 (67) 305 (72) 290 (95)
Overseas 163 (32) 118 (28) 32 (27)
Not stateda 6 (1) 2 (.2) 2 (100)
aUnknown: insufficient information in the database.
Data represents number (%) of subjects. MSM, men who have sex
with men; Percentages in last column are proportion B compared to
non-B. Genotyped sample was representative of the total population
diagnosed.
FIG. 1. Proportion HIV-1 subtypes in new diagnoses be-
tween 2000 and 2010.
FIG. 2. Proportion of non-B diagnoses in Australia between
2000 and 2010, including local transmission.
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< 25 years cohort was 64% greater than expected, compared to
B infections in the same cohort (20% smaller than expected)
( p= 0.01). The majority (77%) of the 13 young females had a
non-B infection, in comparison to 25% of the young males.
Region of origin
People born in Australia constituted 57% (240/425) of the
genotyped cohort and subtype B accounted for 88% (211/240)
of these infections (Table 1). Of these Australian born subtype
B patients, 77% (163/211) were acquired in Australia. In
contrast, of the 12% (29/240) of Australian born people with a
non-B infection, 66% acquired their infection overseas.
One hundred (24%) people in the genotyped cohort were
born overseas while 20% had no recorded country of birth. In
the overseas born white population, subtype B accounted for
81% of European born people (21/26), of which 91% were
acquired in Australia. Subtype B accounted for 86% of
American born people (6/7), but half of these infections were
acquired overseas. All non-B infections in both European and
American born individuals were acquired overseas.
Nearly all (40/43) African born people had a non-B infec-
tion and 98% of these were acquired overseas. The predomi-
nant non-B infection was C (51%), followed by CRF_AG
(21%), A (16%), CRF_AE (2%), and D (2%). Two-thirds (16/
24) of Asian born people had a non-B infection and 75%
of these were acquired overseas. The predominant non-B
infections were CRF_AE (63%), C (19%), CRF_AG (13%), and
A (5%).
Subtype associations with comparator variables
Multivariate logistic regression analyses were conducted,
taking subtype B infections as the baseline group for compar-
ison and controlling for other independent variables (acquired
overseas, heterosexual, overseas born, and age < 25 years).
As shown in Table 2, there was a strong association be-
tween subtype C and overseas acquisition, with subtype C
infections 34 times more likely than subtype B to be acquired
overseas (95% CI 5.8–192.0, p < 0.0001). Non-B infections were
17 times more likely to be acquired overseas compared to B
infections (95% CI 6.9–42.6, p< 0.0001). Non-B infections were
almost 21 times more likely than B infections to be acquired
through reported heterosexual transmission (95% CI 7.5–57.0,
p < 0.0001), which rose to 44 times more likely for subtype C
cases (95% CI 5.0–384.6, p = 0.001). Non-B infections were al-
most four times more likely (95% CI 1.5–9.9, p= 0.006) among
people born overseas, though this was not significant for
CRF_AE infections alone (95% CI 0.7–7.9, p = 0.146). The age
at diagnosis of HIV infection was not different between B
and non-B patients, except in the ‘‘Other’’ category, which
was subtype A, D, and CRF_AG ( p < 0.05). There were
24 patients with A, D, or CRF_AG: four born in Australia,
17 born in Africa, and three born in Asia. Of these, 38% were
under 25 years of age at detection of infection; 75% (3/4)
from Australia, 24% (4/17) from Africa, and 66% (2/3) from
Asia.
Discussion
This is the first Australian study to investigate genotypic
diversity and trends in subtype distribution of the HIV epi-
demic over the past 10 years. At present, no formal national
HIV-1 molecular surveillance program exists in Australia.
However, South Australia has implemented routine baseline
drug resistance testing, providing viral sequence data com-
bined with notification information to yield an enhanced
comprehension of South Australian HIV molecular epidemi-
ology.21 As HIV continues to evolve, migration patterns
change, and tourism increases, it is important to monitor this
geographic diversity in order to understand and respond to
transmission patterns.5,17
Despite ongoing programs and improved access to testing
and treatment, the rate of new HIV infections remains stable.
However, differences were identified in subtype prevalence,
place of acquisition, region of birth, gender, and age at diag-
nosis. The main finding of this study is that the proportion of
non-B infections has increased in Australia over the past de-
cade. Non-B patients represented approximately a quarter of
the cases in this study, but this proportion had risen to nearly
half of all new diagnoses in 2010. This is similar to a European
report in which more than 60% of new infections were non-B
in 2008.6
The current study demonstrates that patients infected with
B or non-B subtypes represent highly distinct populations.
The majority of B-infected people were MSM, while non-B
infections were mainly heterosexually acquired and just over
a third of were female. Most B infections were acquired in
Australia by people born in Australia while the majority of
non-B infections were acquired overseas by people born
overseas or people traveling to areas of high HIV preva-
lence.5,6 These figures are comparable to findings by Chalmet
et al. (2010) in Belgium, in a similar sized cohort.22
Table 2. Multivariate Odds Ratios in Newly Diagnosed HIV Patients, 2000–2010, When Compared
to the Proportion of Subtype B Infections
Characteristicsa (comparator group)
Clade Acquired overseas (acquired Australia) Heterosexual (MSM) Overseas born (Australian born) Age < 25 ( ‡ 25)
Non-B 17.1 (6.9–42.6) 20.6 (7.5–57.0) 3.8 (1.5–9.9) 3.8 (0.9–15.1)
CRF_AE 17.1 (5.9–49.1) 17.0 (5.1–57.0) 2.4 (0.7–7.9) 2.0 (0.1–14.3)
C 33.5 (5.8–192.0) 44.0 (5.0–384.6) 5.4 (1.2–24.2) 3.4 (0.3–42.8)
Other 7.3 (1.2–46.4) 44.1 (4.6–420.7) 22.5 (2.9–175.4) 27.6 (2.6–295.8)
a95% CIs are indicated in parentheses.
Proportion of subtype B infections was used as the baseline for comparison. All associations in the first three columns were statistically
significant at p< 0.05 except born overseas and CRF_AE ( p< 0.146). In the age column, only the association between other and age < 25 was
significant ( p< 0.05). Non-B includes all non-B subtypes and CRFs. Other consists of subtypes A, D, and CRF_AG. MSM, men who have sex
with men.
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White MSM with locally acquired subtype B continue to
represent the largest HIV risk group in South Australia,
supporting epidemiological trend analyses in Australia, Ca-
nada, Europe, and the United States.15,21–25 There is also a
small subset of MSM acquiring non-B infections overseas and
locally, reflecting findings in the U.K.8 and the recent Victo-
rian study.20 Though national HIV incidence has remained
stable in the MSM population over the past decade, the pro-
portion of undiagnosed infections in South Australia is esti-
mated to be around 20%.26
On a global scale, heterosexual transmission is the major
route of HIV infection.27 In South Australia we are seeing a
shift in the epidemic toward this: a decrease in the local rep-
resentation of MSM and an increase in the representation of
heterosexual men and women, including a large proportion
from sub-Saharan Africa. This shift has also been noted in
Europe.28 Since 2000, heterosexually acquired infections have
doubled to nearly half of all new diagnoses, not quite as high
as the 4-fold increase seen in the U.K. since 1996.21 Most non-B
patients contracted HIV by heterosexual contact, and a small
number through male-to-male sex. The proportion of women
infected with subtype B was very low; this can be partly ex-
plained by the high representation of MSM in the B cohort,
while themajority of females acquired their infection overseas
where non-B subtypes are more frequently circulating.
Despite the apparent shift in the South Australian epidemic
toward increasing heterosexually acquired non-B HIV infec-
tions, MSM are still a critical at-risk population that justifies a
continued prevention and intervention focus for scientists,
program experts, and policy makers.15
Corresponding with an increase in heterosexual infections,
there has been a significant increase in imported non-B in-
fections, through migration or travel to countries where there
is a high prevalence of HIV. Though the numbers are small,
there is evidence of non-B local transmission, predominantly
found in females. A significantly higher proportion of non-B
patients was diagnosed under the age of 25 compared to the B
cohort, though when location acquired, country of birth, and
risk behavior were controlled for, this was significant only for
subtype A, D, and CRF_AG patients. These clades are com-
mon in Africa and Asia, where two-thirds of these young
patients were born. Patients born in Africa reported sexual
contact as their risk exposure while the two patients born in
Asia were both under 10 years of age, with overseas medical
procedure cited as the risk exposure.
Transmission of non-B subtypes and CRFs is rapidly ex-
panding geographically, and the rise in non-B diagnoses may
be a marker of more recent transmission events—some at-
tributed to tourism and some to importation by people born in
high prevalence countries where multiple subtypes and CRFs
circulate.
Over half of the global HIV population is infected with
subtype C,4,29,30 which is dangerously uncontrolled in Africa
and India. Subtypes A and B follow, then CRF_AG and
CRF_AE, the latter predominantly found in Asia.9,30 In our
cohort, subtype C accounted for fewer than 10% of total in-
fections but over a third of non-B infections. Nearly all were
reportedly acquired overseas, and though information on a
specific country was not available, a large percentage of these
patients originated from Africa.
The predominant non-B infection was CRF_AE, with
prevalence in the genotyped cohort twice that of the 5% global
average, and almost all cases reportedly were acquired
overseas. Hemelaar et al. found global CRF infections in-
creased by over 50% between 2000 and 2007,9,30 and the
current study reflects this temporal CRF increase; almost half
the AE infections were diagnosed in 2007–2010. Unlike sub-
type C, nearly half the patients were born in Australia and
were most likely the result of acquisition during overseas
travel to Asia.
Subtypes A, D, and CRF_AG are predominantly found in
Africa, with a combined global prevalence rate of 10%.9
Though prevalence was relatively low in our cohort, nearly all
were diagnosed in the latter time period, and were acquired
overseas by people of African origin, possibly reflecting the
increase in Australian migration from this region. A number
of Australian born heterosexual men and women also im-
ported or locally acquired subtypes D and CRFs AE and AG.
These findings have public health implications, both for
targeting specific at-risk populations and assessing the po-
tential increase of non-B subtypes within the domestic HIV-1
epidemic.1
There are scarce data available on subtype differences and
even fewer data available on non-B subtypes in developing
countries where they are the major infection type. There is
growing evidence, however, that suggests HIV strains do
differ from each other in terms of virulence, transmission, or
rate of progression.4 A 10-year prospective study in Senegal
found female sex workers with a non-A subtype had a sig-
nificantly shorter AIDS-free survival time.31 A 2010 London
study found a CD4 cell decline 4-fold faster in subtype D
patients, and a higher virological rebound at 6 months, after
adjustment for baseline, gender, and ethnicity.21 A study of
Kenyan women found a >2-fold higher risk of mortality and
faster rate of CD4 cell decline in D patients compared with A,
after adjustment for viral load,32 and in a Ugandan cohort,
subtypeD patients tended to developAIDS earlier.33 In Rakai,
themedian time to onset and risk of progression to deathwere
significantly shorter for subtype D and CRF patients com-
pared with A.11 Each of these studies concluded that HIV
disease progression is affected by subtype and that this may
have an impact on decision and policy making in terms of
initiation of therapy and future vaccine trials.11,21,32
Understanding genetic diversity is very important for the
treatment of non-B subtypes. Many researchers now agree
that though it appears subtypes and CRFs are equally sensi-
tive to treatment, transmitted polymorphisms present before
therapy may affect subtype-specific pathways of secondary
resistance.12 This combined with suboptimal therapy and
poor adherence in developing countries makes them a prime
target for accelerated drug resistance, both acquired and
transmitted.34 Current drug regimens targeted against sub-
type B may not be equally effective long term for non-B sub-
types and may lead to faster drug resistance.27
Interpreting and reporting surveillance data can be prob-
lematic. Reporting newly acquired infections does not dem-
onstrate true reductions or increases in the wider community;
HIV diagnoses represent only the subgroup of people who
have willingly been tested and had an HIV-positive result.
These individuals are often those who have easy access to
medical health services and are concerned about their own
risk behavior.35 Immigrants, visa holders, and refugees still
face barriers to accessing health services for screening and
treatment of HIV, arising from stigma, financial restrictions,
EPIDEMIOLOGY OF NON-B CLADE INFECTION 5
Archived at Flinders University: dspace.flinders.edu.au
limited support systems and English skills, and residency
concerns.28,35 Refugees in particular may be difficult to reach
because of traumatic life experiences prior to arrival in
Australia.
This is a major concern as the UN recognizes migrants as
one of the groups most vulnerable to HIV, and overseas born
people now comprise a third of HIV notifications in Aus-
tralia.28,36 These issues along with a continuing influx of new
arrivals from high HIV prevalence and low/middle income
countries are likely to lead to an underestimate of HIV in-
fections in these populations, a possible increase in local
transmission of non-B subtypes, and poor treatment adher-
ence, which could lead to transmitted drug resistance.1,36
The global spread of HIV diversity is highly dynamic with
regard to epidemiological factors such as risk group and
geographic location; it continually generates through muta-
tion and recombination, and then travel and migration assist
in the transfer of this diversity between populations.21 Our
analyses focused exclusively on pol, as it is routinely used for
drug resistance testing, and provided the largest possible
reference dataset of B and non-B subtype sequences. We note
that further subtype validation should be conducted with
alternative HIV genes, such as env.37 Ongoing surveillance
and a deeper understanding of HIV variation, including fac-
tors and molecular mechanisms that affect transmission,
replication, and resistance, are crucial for the development of
appropriately targeted subtype-specific prevention and
treatment options for populations most at risk.5,9,21,29 Further
evidence of subtype differences could drastically change the
way we respond to the HIV epidemic.
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